Dr. Richard Novak, a principal investigator for a Moderna vaccine trial at UI Health says myocarditis is usually caused by a viral infection. It occurs about one or two in every 10,000 people. So, it’s not terribly rare, said Dr. Novak. Often times, it’s a complication of a virus.
Dr. Novak says COVID-19 is known to cause the heart condition. He believes it s too early to tell if the vaccine plays any role in causing it.
Meanwhile, Dr. Wayne Franklin of Loyola University Medical Center says the reported cases have been mild. While severe cases can lead to hypertension or cardiac failure, Dr. Franklin says it shouldn t deter anyone from getting the vaccine.
Myocarditis is an inflammation of the heart muscle that decreases the ability of the heart to pump blood normally, according to Harvard Health. Medical experts say the condition is usually caused by viral infections but can also be the body’s reaction to a drug. We ve not seen reports of that locally here, Arwady said. We have asked doctors just to be on the lookout if we were to see it, but this is not like when the [Johnson & Johnson vaccine] was paused. This is sort of, you know, more of just be aware in case we were to see anything, but I don t have any concerns about it based on what we ve seen at this point.
The majority of cases have largely been reported after the second dose, typically within four days after vaccination.
The panel notes that most cases appear to be mild, and follow-up of cases is ongoing, but it did not offer details on how many cases have so far been reported. Within CDC safety monitoring systems, rates of myocarditis reports in the window following COVID-19 vaccination have not differed from expected baseline rates, the panel stated. However, VaST members felt that information about reports of myocarditis should be communicated to providers.
Myocarditis is an inflammation of the heart muscle that decreases the ability of the heart to pump blood normally, according to Harvard Health. It can be caused by a number of things, including viral infections, bacteria, lyme disease, chagas disease and certain medications.
E-Mail
IMAGE: A research team at the Wyss Institute and Harvard Medical School has developed a nasal swab collection technology enabling high-throughput automated sample processing for molecular diagnosis of respiratory diseases including. view more
Credit: Wyss Institute at Harvard University
(Boston) The Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) and the Massachusetts-based startup Rhinostics announced today that the University s sample collection swab and high-throughput automation technologies have been licensed to Rhinostics. The company will further develop and commercialize automated and multiplexed solutions for processing nasal samples from people suspected to have COVID-19 or other respiratory infectious diseases. The license was coordinated by Harvard s Office of Technology Development (OTD) in accordance with the University s commitment to the COVID-19 Technology Access Framework.
Harvard University licenses its nasal swab collection technology, developed at the Wyss Institute and Harvard Medical School, to Mass startup Rhinostics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.